Suárez García, InésAlejos, BelénMoreno, CristinaMiguel, Rosa deAldámiz Echevarría, TeresaGarcía Fraile, Lucio JesúsTasias, MaríaPérez Martínez, DesiréeAntela, AntonioMoreno, SantiagoEt. al.2026-02-022026-02-022025Suárez‐García, I., Alejos, B., Moreno, C., De Miguel, R., Aldámiz‐Echevarría, T., García‐Fraile, L. J., Tasias Pitarch, M., Pérez Martinez, D., Antela, A., Moreno, S., Jarrín, I., & CoRIS cohort. (2025). Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort. HIV Medicine, hiv.70183. https://doi.org/10.1111/hiv.701831468-12931468-1293https://hdl.handle.net/11268/16779To evaluate the effectiveness and tolerability of dolutegravir/lamivudine (DTG/3TC) at 96 weeks in virologically suppressed persons with HIV, both overall and across subgroups, within CoRIS, a large multicenter cohort in Spain, in 2018–2023. We included treatment-experienced adults with HIV who were virologically suppressed (viral load <50 copies/mL) when switching to DTG/3TC. We calculated the proportion maintaining viral suppression (VS), change in CD4 cell counts, virological failure (VF; two consecutive viral load (VL) ≥50 copies/mL or one ≥1000 copies/mL), and discontinuations due to adverse events (AEs) up to 96 weeks post-switch. Outcomes were stratified by sex, age, region of origin, antiretroviral regimen at switch, and previous VFengDolutegravirRespuesta Virológica SostenidaEstudios de cohortesjournal article10.1111/hiv.70183embargoed accessSidaMedicamentoInvestigación médicaGoal 3: Ensure healthy lives and promote well-being for all at all ages